Journal of experimental therapeutics & oncology · 2018
Anticancer activity of chlorhexidine and cranberry extract: an in-vitro study.
Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khairnar Mahesh R, Wadgave Umesh, Jadhav Harish, Naik Rahul
Аннотация
INTRODUCTION: Oral cancer is considered to be a global pandemic. The study was conducted to assess the anti-cancer activities of Chlorhexidine (CHX) and Cranberry against oral cancer cell lines.
MATERIAL AND METHODS: Anticancer activity of CHX and Cranberry extract (CE) was assessed against AW13516 (poorly to moderately differentiated squamous cell carcinoma of tongue) and KB (Nasopharyngeal carcinoma) using Sulforhodamine B (SRB) assay at the Advanced Centre for Treatment Research and Education in Cancer (ACTREC) Mumbai, India. Three dose related parameters GI50, TGI and LC50 were calculated for each drug.
RESULTS: CE (80µg/ml) showed no anti-cancer property against AW13516 cell line; however it showed 70.6% growth inhibition against KB cell line. CHX demonstrated 80.15% & 95.7% of growth inhibition against AW13516 & KB cell line respectively. Both the drugs were less potential than positive control drug Adriamycin, as reflected by their GI50, TGI and LC50 values.
CONCLUSION: CHX exhibited better anti-cancer properties than CE for both the oral cancer cell lines.
MATERIAL AND METHODS: Anticancer activity of CHX and Cranberry extract (CE) was assessed against AW13516 (poorly to moderately differentiated squamous cell carcinoma of tongue) and KB (Nasopharyngeal carcinoma) using Sulforhodamine B (SRB) assay at the Advanced Centre for Treatment Research and Education in Cancer (ACTREC) Mumbai, India. Three dose related parameters GI50, TGI and LC50 were calculated for each drug.
RESULTS: CE (80µg/ml) showed no anti-cancer property against AW13516 cell line; however it showed 70.6% growth inhibition against KB cell line. CHX demonstrated 80.15% & 95.7% of growth inhibition against AW13516 & KB cell line respectively. Both the drugs were less potential than positive control drug Adriamycin, as reflected by their GI50, TGI and LC50 values.
CONCLUSION: CHX exhibited better anti-cancer properties than CE for both the oral cancer cell lines.
Предметные рубрики MeSH
Antibiotics, AntineoplasticAntineoplastic Agents, PhytogenicCarcinomaCarcinoma, Squamous CellCell DifferentiationCell Line, TumorCell ProliferationChlorhexidineDose-Response Relationship, DrugDoxorubicinFruitHead and Neck NeoplasmsHumansInhibitory Concentration 50Nasopharyngeal CarcinomaNasopharyngeal NeoplasmsPlant ExtractsSquamous Cell Carcinoma of Head and NeckTongue NeoplasmsVaccinium macrocarpon